Investors Eye Axogen as FDA Decision on Avance Nerve Graft Nears
Axogen’s Avance nerve graft faces an upcoming FDA decision that could reshape adoption, reimbursement and revenue prospects, drawing close investor scrutiny.
Seeking Alpha
2 min read
Stocks
Medical Devices
Biotech